Gary Nabel, MD, PhD, Chief Scientific Officer and Senior Vice President of Sanofi, will deliver the next Flexner Discovery Lecture on Thursday, Nov. 14.
Scientists are testing a new way to fight chikungunya virus that involves injecting genetic material into the bodies of infected and at-risk individuals to trigger rapid production of potent, virus-neutralizing antibodies.
Mark Boothby and colleagues are exploring the factors that contribute to antibody production and quality, which are key to our defense against pathogens and response to vaccines.
Vanderbilt researchers have discovered that IgM-type antibodies appear to play a protective role to prevent the development of type 1 diabetes — and that purified IgM antibodies can reverse the disease.
New research links nutrient-responsive cellular signaling to the antibody-mediated immune response.
Researchers at Vanderbilt University Medical Center and Washington University School of Medicine in St. Louis have isolated a human monoclonal antibody that in a mouse model “markedly reduced” infection by the Zika virus.
Accessibility Tools